Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

BACKGROUND: Innovative coronavirus disease 2019 (COVID-19) vaccines, with elevated global manufacturing capacity, enhanced safety and efficacy, simplified dosing regimens, and distribution that is less cold chain-dependent, are still global imperatives for tackling the ongoing pandemic. A previous p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Ya-Jun, He, Jian-Feng, Pei, Rong-Juan, He, Peng, Huang, Zhu-Hang, Chen, Shao-Min, Ou, Zhi-Qiang, Deng, Jing-Long, Zeng, Pei-Yu, Zhou, Jian, Min, Yuan-Qin, Deng, Fei, Peng, Hua, Zhang, Zheng, Wang, Bo, Xu, Zhong-Hui, Guan, Wu-Xiang, Hu, Zhong-Yu, Zhang, Ji-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382383/
https://www.ncbi.nlm.nih.gov/pubmed/34310400
http://dx.doi.org/10.1097/CM9.0000000000001702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382383/
https://www.ncbi.nlm.nih.gov/pubmed/34310400
http://dx.doi.org/10.1097/CM9.0000000000001702

Ejemplares similares